Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
about
Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep ModelApplication of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic ClearanceOptimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors.Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent.Cellular asymmetric catalysis by UDP-glucuronosyltransferase 1A8 shows functional localization to the basolateral plasma membraneChemoenzymatic Synthesis, Characterization, and Scale-Up of Milk Thistle Flavonolignan Glucuronides.Retracted: Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo.Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In VivoScaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearanceProbe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery.Recent results in alamethicin research.The role of drug metabolizing enzymes in clearance.Extrahepatic metabolism at the body's internal-external interfaces.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance.A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans.The Inhibition of Hepatic and Renal Glucuronidation of p-Nitrophenol and 4-Methylumbelliferone by Oil Palm Empty Fruit Bunch Lignin and Its Main Oxidation Compounds.Revisiting the Latency of Uridine Diphosphate-Glucuronosyltransferases (UGTs)-How Does the Endoplasmic Reticulum Membrane Influence Their Function?Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans.Comparison of intestinal metabolism of CYP3A substrates between rats and humans: application of portal-systemic concentration difference method.Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys.To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.In Vitro Drug Metabolism Using Liver Microsomes.In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes.Simultaneous analysis of gemfibrozil, morphine, and its two active metabolites in different mouse brain structures using solid-phase extraction with ultra-high performance liquid chromatography and tandem mass spectrometry with a deuterated internalThe Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance.Unequivocal evidence supporting the segregated flow intestinal model that discriminates intestine versus liver first-pass removal with PBPK modeling.Physiologically-based pharmacokinetic predictions of intestinal BCRP-mediated drug interactions of rosuvastatin in Koreans.
P2860
Q28552505-B7115251-4559-4C19-A035-E652685AB323Q30585329-A2FAD8E6-E70F-4F45-B86F-CA4956060680Q33588394-5B35D480-41E2-476A-9449-DDCD72B888A4Q33628703-2733AF86-A46D-44E6-8699-8EB8CAE48A28Q34571313-221C6197-76D9-4119-B5F6-7201021BAEB5Q35199391-251D20D3-133A-42F9-BEAB-B61A9D05E2D1Q36186132-B6D42F00-6FCD-4397-AD18-BCC9BD4987E7Q36233941-E0B2037F-7B8B-441E-B184-0E0BB2A93724Q36346340-3B8F13A4-97B5-4498-89D9-770CDF0E33C8Q36737009-BA46C988-8913-44D7-A88D-2506340BC4F5Q36924729-899AE320-311D-4044-92E8-E337A2EB3E2EQ38017309-CB650A73-2A8F-42F3-B5A4-473916B8F580Q38107441-911196D6-716C-4721-BC99-43888ACAA5D0Q38176051-A06177ED-2D5E-434E-8D18-FD5701BD083AQ38199198-FFA60220-2D1C-4799-93C2-9CDF7589CBEDQ38798449-4D96E162-2B1B-4400-BFC5-A2D67EE98292Q38799423-7B954177-004C-4691-949B-7CD3F54743CBQ38887625-71F53541-B89F-48D7-8172-FD785BD76FF0Q40359652-E770E235-92F3-4B9B-AEE0-8457D6FB62EAQ41128320-90E41F9C-BE32-4B4E-A601-8F5A097C2F9BQ41911401-D5BDE0EB-48A3-4768-85CF-FC1395B5EB05Q41941451-EF5233CC-224B-4AE8-BF9F-F50DEEFDB753Q43730577-BD368E8E-5445-406F-A763-AA547D73344BQ45263024-2604A715-87F7-40C2-91B1-71D163BBA071Q46556849-11CC7564-9867-4F47-A389-7B7E05053A8BQ50871327-7940FF05-5AF5-4AC6-A386-5D594063764FQ51499112-AFF39207-F45F-4003-B9C9-12964F414885Q51643121-F5BD0025-34F3-45E9-A472-69FD0F854001Q52141284-C5A3596F-B9FB-4012-A5CF-29F94CBCC977Q53233045-B837656F-6315-4329-A774-4AA2A947E2E6Q53630136-8547831C-8FCF-41BC-9FC6-2F4FAD7DD5F4Q55518566-99F2D7CE-3C0B-42FF-942D-67C6491570DE
P2860
Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Characterization of in vitro g ...... idation and impact of albumin.
@ast
Characterization of in vitro g ...... idation and impact of albumin.
@en
type
label
Characterization of in vitro g ...... idation and impact of albumin.
@ast
Characterization of in vitro g ...... idation and impact of albumin.
@en
prefLabel
Characterization of in vitro g ...... idation and impact of albumin.
@ast
Characterization of in vitro g ...... idation and impact of albumin.
@en
P2093
P2860
P356
P1476
Characterization of in vitro g ...... idation and impact of albumin.
@en
P2093
Aleksandra Galetin
J Brian Houston
Katherine L Gill
P2860
P304
P356
10.1124/DMD.111.043984
P577
2012-01-24T00:00:00Z